Results 301 to 310 of about 283,224 (387)

Should Induction Chemotherapy Be Considered First‐Line Therapy for Sinonasal Undifferentiated Carcinoma?

The Laryngoscope, EarlyView.
Daniel X. Ma, Shirley Y. Su, Bobby A. Tajudeen, Edward C. Kuan   +3 more
wiley   +1 more source

Pan‐ERBB Inhibitors Synergize With KRAS Inhibitors in Rectal Cancer

United European Gastroenterology Journal, EarlyView.
ABSTRACT Background Emerging RAS inhibitors show promise in treating KRAS‐mutated malignancies, but resistance mechanisms limit their clinical efficacy. Given recent clinical findings associating KRAS mutations with reduced response to neoadjuvant therapy in rectal cancer (RC), we aimed to investigate their impact on treatment outcomes and explore ...
Jonas Buchloh, Melanie Spitzner, Hauke Zimmermann, Xin Fang, Constanza Tapia Contreras, Carolin Schneider, Tiago de Oliveria, Stefan Küffer, Michael Linnebacher, Felix Rühlmann, Lena Conradi, Matthias Wirth, Michael Ghadimi, Marian Grade, Jochen Gaedcke, Günter Schneider   +15 more
wiley   +1 more source

Effect of 5-fluorouracil on <i>Pseudomonas aeruginosa</i>: impact on virulence, biofilm formation, and bacterial growth. [PDF]

Front Microbiol
Niazy AA, Alrashed MM, Niazy AA.
europepmc   +1 more source

Toward Precision Chemotherapy for Pancreatic Cancer Guided by Transcriptomic Signatures

United European Gastroenterology Journal, EarlyView.
ABSTRACT Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, with chemotherapy as the mainstay but highly variable efficacy and toxicity. Current regimens, such as FOLFIRINOX and gemcitabine‐based combinations, are selected empirically without validated biomarkers to guide choice.
Brice Chanez, Matthieu Delaye, Nicolas Fraunhoffer, Juan Iovanna, Cindy Neuzillet, Nelson Dusetti   +5 more
wiley   +1 more source

Organoid‐based novel technology for antitumor drug screening

VIEW, EarlyView.
Organoids represent a cutting‐edge research model that closely mimics in vivo organ physiology, making them highly valuable for tumor immunotherapy drug screening. This review explores the integration of organoids with advanced technologies, such as gene editing, 3D bioprinting, and AI, highlighting novel fusion platforms and their applications.
Yu Su, Yuan Chen, Guanning Wei, Yihai Shi   +3 more
wiley   +1 more source

Cardiotoxicity Conundrum: Distinguishing Immune Checkpoint Inhibitor Myocarditis From Fluorouracil Cardiotoxicity in Concurrent Therapy. [PDF]

JACC Case Rep
Hu V, Naidu I, Singh N, Akinmolayemi O, Sahni G.   +4 more
europepmc   +1 more source

Impact of TP53, KRAS, and APC Mutations on Neoadjuvant Chemotherapy Outcomes in Locally Advanced Rectal Cancer

Cancer Science, EarlyView.
Genetic profiling of TP53, KRAS, and APC mutations reveals potential as predictors of neoadjuvant chemotherapy efficacy in locally advanced rectal cancer, aiding personalized treatment strategies to improve survival and reduce recurrence risks. ABSTRACT Despite recent advances in neoadjuvant strategies for locally advanced rectal cancer (LARC), optimal
Tomohiro Takeda, Tatsuya Shonaka, Mishie Tanino, Katsuro Enomoto, Shoichiro Mizukami, Masahide Otani, Mizuho Ohara, Chikayoshi Tani, Kimiharu Hasegawa, Takahiro Ishii, Ayumu Sugitani, Chiho Maeda, Yusuke Ono, Yuji Uno, Nobue Tamamura, Shin‐ichi Chiba, Yusuke Mizukami, Hideki Yokoo   +17 more
wiley   +1 more source

Determination of 5-Fluorouracil in Dried Blood Spots for Therapeutic Drug Monitoring and Adverse Event Assessment in Breast Cancer Patients. [PDF]

Clin Pharmacol
Hanifah M, Harahap Y, Purwanto DJ.
europepmc   +1 more source

Anticancer Effect of the Triphenylphosphonium‐Conjugated Quinolone Antibiotics Targeting Mitochondrial DNA Replication

Cancer Science, EarlyView.
Mitochondrial DNA replication‐targeting quinolone derivatives, termed MitoQNs, are synthesized. They exhibit reduced antibacterial activity and enhanced anticancer efficacy and thus could be candidate drugs for cancer therapy. ABSTRACT Antibacterial quinolones are widely used to treat bacterial infections in humans.
Yuming Qiao, Yuki Kida, Xiaoyi Lai, Nobuko Koshikawa, Rie Igarashi, Atsushi Takatori, Keizo Takenaga   +6 more
wiley   +1 more source

Treatment discontinuation associated with perioperative toxicity of FLOT versus XELOX chemotherapy in patients with resectable gastric cancer: prospective randomized trial (PECORINO). [PDF]

J Gastrointest Oncol
Dobrzhanskyi O, Kopetskyi V, Ross EA, Chernoff J, Shudrak Y, Kolesnyk A, Pepenin M, Horodetskyi A, Melnitchouk N, Kondratskyi Y.   +9 more
europepmc   +1 more source